Obsidian Therapeutics

Obsidian Therapeutics is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company developing engineered tumour-infiltrating lymphocyte (TIL) cell therapies for solid tumours, using its cytoDRiVE protein-regulation platform to control engineered proteins with approved small-molecule drugs. Its lead candidate, OBX-115, is in a Phase 1/2 study in advanced melanoma. Founded in 2015, it became a Nasdaq-listed company (OBX) in August 2026 through a reverse merger with Galera Therapeutics.